Abstract:
Compounds of Structural Formulae I, II, III, IV, V, VI, VIa, VIb, VII, and VIII were developed for the treatment of Ebolavirus infection, wherein, R1, R2, R8, X, Y, Q, W, and NR3aR3b are defined in the specification.
Abstract:
The invention relates to compounds of structural formula I, wherein A, D, and E are independently N or C-R 3 , G, H, and J are independently N or C, K is N or C-H, L is N, N-R 3 or C-R 3 , and A, D, E, G, H, J, K, and L together cannot have more than 4 N, R 1 is selected from (C 6 to C 10 ) aryl, (C 2 to C 9 ) heteroaryl, and 5-indolyl, wherein each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is substituted with at least one R 4a group, and wherein said (C 2 to C 9 ) heteroaryl is C-attached, and R 2 is selected from the group consisting of (i), (ii), (iii), and (iv).
Abstract:
The invention relates to compounds of structural formula I, wherein A, D, and E are independently N or C-R 3 , G, H, and J are independently N or C, K is N or C-H, L is N, N-R 3 or C-R 3 , and A, D, E, G, H, J, K, and L together cannot have more than 4 N, R 1 is selected from (C 6 to C 10 ) aryl, (C 2 to C 9 ) heteroaryl, and 5-indolyl, wherein each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is substituted with at least one R 4a group, and wherein said (C 2 to C 9 ) heteroaryl is C-attached, and R 2 is selected from the group consisting of (i), (ii), (iii), and (iv).
Abstract:
The invention relates to compounds of structural formula I wherein A is independently N or C-R3, R1 is selected from (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) heterocycloalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl, wherein each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) heterocycloalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group, and wherein said (C2 to C9) heteroaryl is C-attached, and R2 is selected from the group consisting of Formula (II), Formula (III), Formula (IV), Formula (V) and formula (VI)..
Abstract:
Compounds as exemplified by compound A are useful in the treatment of arenavirus infections and viral infections mediated by arenavirus glycoproteins.
Abstract:
The compounds of the invention as shown by general structure I, as shown below, are effective in treating filovirus infections. Structure I X is selected from the group consisting of O and H; R 1 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, and R 2 is selected from (C 1 to C 10 ) alkyl, (C 1 to C 10 ) alkenyl, (C 1 to C 10 ) alkynyl, (C 3 to C 10 ) cycloalkyi, and (C 5 to C 10 ) cycloalkenyl, and NR 3a R 3b is defined in the specification. These compounds are effective in treating filovirii infections including Ebolavirus and Marburgvirus.
Abstract:
The present invention relates to the use of piperazinones for inhibiting arenavirus infection in humans, other mammals, or in cell culture, to methods of treating arenavirus infection such as Lassa, Bolivian, Argentine, Venezuelan, Brazilian, Chapare and Lujo hemorrhagic fevers, to methods of inhibiting the replication of arenaviruses, to methods of reducing the amount of arenaviruses, and to compositions that can be employed for such methods.